An observational study in Asthma (Diagnosis) and Community-Acquired Pneumonia (CAP), sponsored by Shanghai Children's Medical Center. Not yet recruiting at 1 site in China. Open to participants aged 28 Days to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Shanghai Children's Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.
Among the 251 studies in Asthma with a site in China, this one is the 16th largest by planned enrollment of the 69 observational ones that give a count, is one of 20 that started in 2026, is one of 69 observational ones, reaches primary completion later than 90 of the 95 other live ones, and was the 237th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 2 more countries
Ages 18–85
AstraZeneca · Sites in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 28 Days to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 46 · Phase 3 50 · Phase 4 18
First in 1998; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,400 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 203 across the 182 interventional studies, 407 across the 69 observational. Of the 116 that completed or were terminated, 30 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 251 have an industry lead sponsor. The 10 most frequent:
Shanghai Children's Medical Center is the lead sponsor of 38 studies on the registry; 14 are open to participants now.
Shanghai Children's Medical Center has 5 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
28 of the studies in Asthma with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06323213Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Efficacy and Safety Study of 610 in Patients With Severe Asthma | 2027-02 |
| NCT06895460Phase 3The First Affiliated Hospital with Nanjing Medical UniversityA Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) | 2027-06-30 |
| NCT06653322Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | 2027-09 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
Add all 28 to your calendar (.ics) → With an account.
Among the 251 studies in Asthma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, this study will develop and validate a multimodal assisted diagnostic model for common pediatric respiratory diseases based on symptom questionnaires, cough sounds, and breath sounds. The study will primarily evaluate the diagnostic performance of the model in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis/bronchitis, upper airway-related diseases, and common causes of chronic cough. It will also assess the incremental value of cough sounds and breath sounds beyond symptom questionnaire information.
This is a prospective, observational diagnostic accuracy study to be conducted at Shanghai Children's Medical Center. The study population will include children presenting with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints, as well as healthy children recruited during routine health examinations. The study will establish a standardized and synchronized data collection workflow for pediatric symptom questionnaires, cough sounds, and breath sounds. All enrolled participants will complete a structured symptom questionnaire, undergo cough sound recording using a smartphone application, and undergo breath sound recording using an electronic stethoscope under unified protocols. Demographic and clinical information, including age, sex, disease duration, major symptoms, medical history, allergy history, family history, medication use, final clinical diagnosis, or health status assessment, will also be collected to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Based on this database, the study will develop a stepwise multimodal assisted diagnostic framework using a combination of conventional statistical learning and deep learning methods. Three diagnostic models will be constructed and compared: a symptom questionnaire-only model, a symptom questionnaire plus cough sound model, and a multimodal model integrating symptom questionnaires, cough sounds, and breath sounds. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, the study will evaluate the diagnostic performance of these models in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis/bronchitis, upper airway-related diseases, and common causes of chronic cough. Model performance will be assessed using AUC, AUPRC, sensitivity, specificity, positive predictive value, negative predictive value, F1 score, and accuracy. The study will further investigate the incremental value of cough sounds and breath sounds beyond symptom questionnaire information, and assess model stability and generalizability across different age groups, clinical settings, and device conditions. The findings are expected to provide evidence for the optimization, clinical translation, and potential home-based extension of multimodal artificial intelligence-assisted diagnostic models for pediatric respiratory diseases. The study will not interfere with routine clinical care, and the model outputs will not be used for real-time clinical decision-making.
The target population will include children aged 28 days to 18 years, including children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints, as well as healthy children recruited during routine health examinations or children without respiratory complaints. The study population will cover common pediatric respiratory diseases and healthy controls, providing a representative disease spectrum.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Children aged 28 days to 18 years, regardless of sex, will be eligible for inclusion. The disease group will include children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints. Participants should be able to complete the symptom questionnaire, cough sound recording, and breath sound recording, and their guardians must provide and allow review of relevant medical history and diagnostic information. The healthy control group will include children recruited from routine health examinations or children without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks, no known history of chronic respiratory diseases, no obvious respiratory abnormalities on health assessment or research team review, the ability to complete relevant data collection, and guardian informed consent.
Exclusion Criteria:
Participants will be excluded if they have severe cardiopulmonary malformations, long-term tracheostomy or mechanical ventilation, severe neuromuscular disorders, severe immunodeficiency, or other conditions that may substantially alter cough sound characteristics or affect the clinical presentation of respiratory diseases. Children whose primary diagnosis at the current visit is a non-respiratory disease and who are not suitable for this study will also be excluded. Participants who are unable to complete the symptom questionnaire, or whose cough sound or breath sound recordings remain of insufficient quality after repeated attempts, will not be included or will be excluded from the corresponding modality-specific analysis. Participants with only one unavailable modality may be included in analyses based on the completed modalities but will be excluded from analyses requiring the missing modality. Healthy controls will be excluded from the main control analysis if recent respiratory symptoms, a history of chronic respiratory disease, or other conditions that may affect acoustic features are identified.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 28 days to 18 years presenting with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints.
Diagnostic Test: Multimodal respiratory data collection
Children aged 28 days to 18 years recruited from routine health examinations or without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks and no known chronic respiratory disease.
Diagnostic Test: Multimodal respiratory data collection
Participants will complete a structured symptom questionnaire, cough sound recording using a smartphone application, and breath sound recording using an electronic stethoscope. These data will be used to develop and evaluate a multimodal assisted diagnostic model and will not guide real-time clinical decision-making.
Area under the receiver operating characteristic curve of the multimodal assisted diagnostic model
The area under the receiver operating characteristic curve will be used to evaluate the diagnostic performance of the multimodal assisted diagnostic model integrating symptom questionnaire, cough sound, and breath sound data. The model will be assessed against the final clinical research label for distinguishing children with respiratory diseases from healthy controls and for identifying major pediatric respiratory disease categories.
Time frame: Through study completion, an average of 1 year
Area under the precision-recall curve of the multimodal assisted diagnostic model
The area under the precision-recall curve will be used to evaluate the diagnostic performance of the multimodal assisted diagnostic model, particularly in settings with imbalanced disease categories. The model will be assessed against the final clinical research label.
Time frame: Through study completion, an average of 1 year
Sensitivity of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
Specificity of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
Positive predictive value of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
Negative predictive value of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
F1 score of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
Accuracy of the multimodal assisted diagnostic model
Time frame: Through study completion, an average of 1 year
Start is estimated for Jun 2026; primary completion for May 2029, 35 months later.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 35 months is close to that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Children's Medical Center